Best Cardiac and Vascular Disorders Companies in California, United States

Provider of access catheters for cardiovascular diagnosis and treatment. The catheters are used in deep navigation into the blood vessels of the brain to prevent strokes. The flagship product ZOOM Aspiration System is a family of products designed to facilitate clot removal during ischemic stroke.

Funding rounds

• Mar 2026Series E$100M
• Jul 2024Series E$150M
• Jul 2021Series D$260M
• Dec 2019Series C$86M

Founders & team

Dr HopkinsCo-founderFred KhosraviCo-Founder & CEO

Investors

Delos Capital, HealthCor Partners, Ally Bridge Group, Rock Springs Capital, Ascension, Innovatus Capital Partners

Tech stack

Apple Icloud MailAutoptimizeCdnjsCloudflareCloudflare Bot ManagementContact Form 7

BioVentrix develops clinical solutions for treating heart failure patients. It provides PliCath HF, an epicardial catheter-based ventricular reconstruction device. Product is not commercially available.

Funding rounds

• Apr 2026Series E$705K
• Oct 2024Series E$6.7M
• Mar 2024Series E$3.6M
• Apr 2023Series E$48.5M

Founders & team

Lon AnnestCo-FounderDavid RCo-CEO

Investors

Taglich Brothers, Andera Partners, Cormorant Asset Management, Squarepoint Capital, Richmond Brothers, Telegraph Hill Partners

Tech stack

BootstrapCloudwaysGoogle AnalyticsGsapIsotopeJquery

Developer of medical devices for treating mitral valve regurgitation. The company is developing a minimally-invasive trans-catheter hemi-replacement system, PLAR system, to treat insufficiency in the function of the mitral valve.

Funding rounds

• Mar 2026Series C$50M
• Jun 2020Series B$40M
• Jul 2018Series A$25M

Founders & team

Jacques EssingerFounder & CEOJacques EssingerCEO

Investors

Decheng Capital, Endeavour Vision, IDO Investments, Earlybird, Wellington Partners Venture Capital, Longitude Capital

Radiopharmaceutical solutions provider specializing in cyclotron technology and targeted alpha therapy. The company provides full-service radioisotope production and end-to-end radiopharmaceutical manufacturing solutions. It developed a compact superconducting cyclotron used to produce N-13 Ammonia, a PET imaging agent. The company establishes a network of cyclotrons installed near PET programs, making this tracer accessible and affordable. It supports the development and commercialization of targeted alpha therapy (TAT), an emerging cancer therapy utilizing alpha radionuclides. The company is committed to the design, manufacturing, and support of safe and effective radiopharmaceutical products. It offers a turnkey solution eliminating the expense of launching a Cardiac PET program. The company fosters scientific partnerships and sponsorships to deliver advanced radiopharmaceuticals, providing access to scarce diagnostics and therapeutic radiopharmaceuticals.

Funding rounds

• Feb 2026Post IPO$30M
• Aug 2024Series C—
• May 2020Series C$37.3M
• Mar 2018Series B$23.8M

Founders & team

Kevin CameronCEO

Investors

Lilly, Tees River, Riverland Capital

Tech stack

WordpressMysqlPhpThree.JsYoast SeoApache Http Server

Developer of a treatment for hypertrophic cardiomyopathy and related conditions. It focuses on addressing the underlying mechanisms of the condition to improve heart performance. The company is advancing its investigational treatment through late-stage clinical development. Hypertrophic cardiomyopathy causes the heart muscle to become abnormally thick, particularly in the left ventricle.

Funding rounds

• Nov 2025Series A$185M

Founders & team

Travis MurdochCEO & President

Investors

Andreessen Horowitz, Forbion, Orbimed, Enavate Sciences, Frazier Life Sciences

Developer of innovative, versatile, and intuitive medical devices for peripheral vessels treatment

Funding rounds

• Nov 2025Series F$45M
• Aug 2024Series E$32.5M
• Nov 2023Series E$5.7M
• Sep 2021Series E$7.5M

Founders & team

Paul LubockCo-FounderRhonda RobbCEO

Investors

USVP, Vensana Capital, industryveterans, MicroVention, Inari Medical, Sequent Medical

Tech stack

AstraCloudflareCloudflare Bot ManagementCookieyesCore-JsElementor

Stealth Mode: Adagio Medical is a Fjord Ventures portfolio company, based in Laguna Hills. It is focused on the development of cardiovascular therapies. it’s a portfolio company of Fjord Ventures, a technology accelerator that provides venture capital and hands-on support to medical startups.

Funding rounds

• Oct 2025Post IPO$19M
• Nov 2022Conventional Debt$9.5M
• Nov 2020Series E$42.5M
• Mar 2019Series A$7M

Founders & team

Olav BergheimFounder

Investors

ArrowMark Partners, RA Capital Management, Perceptive Advisors, JMR Capital Group, Fjord Ventures

Tech stack

Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai

Transforming cardiac rhythm management with innovative extravascular pacing and defibrillation solutions. This medical device company is dedicated to designing novel extravascular leads and deployment systems, aiming to eliminate the risks and drawbacks of traditional transvenous leads. They focus on both pacing and defibrillation solutions, offering a new option for pacing without entering the heart and life-saving ICD benefits without transvenous leads. Their extravascular solutions place leads outside the vasculature and heart, maintaining the integrity of the heart while delivering much-needed therapy. They are developing the EV Temporary Pacing Lead System and the EV-ICD Lead System, both designed to address pacing and defibrillation needs without entering the heart or vascular system. This innovative approach seeks to reduce complications associated with transvenous leads and improve patient outcomes in cardiac rhythm management. They are focused on medical devices, electrophysiology, cardiology, temporary pacing, extracardiac, and extravascular solutions.

Funding rounds

• Oct 2025Series D$75M
• Apr 2024Series C$28M
• Apr 2020Series B$25M
• Sep 2018Series A$8.8M

Founders & team

Alan MarcovecchioCo-Founder & VP ClinicalRick SangheraCo-Founder & CEOSean McGeehanCo-Founder & CFO

Investors

Broadview Ventures, aMoon, Longview Partners, Hatteras Venture Partners, CHV, Arboretum Ventures

Tech stack

WordpressMysqlPhpLitespeed

Developer of valve replacement solutions. The company is focused on providing elegant valve replacement solutions for mitral and tricuspid applications which use a less invasive, transcatheter approach.

Funding rounds

• Aug 2025Series C$22.9M
• Feb 2023Series C$30M
• Jul 2021Series B$30M
• Apr 2019Series A$15M

Founders & team

Amr SalahiehCo-Founder

Investors

The Capital Partnership, AMED Ventures, ShangBay Capital, Cormorant Healthcare Fund, Cormorant Asset Management, Shifamed

Developer of pulsed electric field systems for various medical indications. The company is developing and commercializing its energy platform for several indications, which include the RheOx system a minimally invasive bronchoscopic therapy for chronic bronchitis, The CENTAURI system for cardiac arrhythmias, and the Aliya system for immuno-oncology and soft tissue ablation.

Funding rounds

• Jul 2025Series C$100M
• Sep 2022Series B$100M
• Mar 2022Series A$4M
• Oct 2020Series A$6.1M

Founders & team

Jonathan WaldstreicherFounder & CEO

Investors

Fidelity Investments, Apple Tree Partners, Intuitive, Gilmartin Capital, Sofinnova Partners, Elevage Medical Technologies

Tech stack

Apple Icloud MailCloudflareCloudflare Bot ManagementCore-JsDocusignDraftpress Hfcm

Eko offers an AI-based platform for remote monitoring of cardiac health. The solution offered by the company collects real-time patient data and analyses it to generate a report for doctors. The report generated aids in providing proper treatment to patients. The company has also developed products like Duo and Core stethoscopes for heart disease monitoring.

Funding rounds

• Apr 2025Grant (prize money)$238.5K
• Jun 2024Series D$41M
• Sep 2022Grant (prize money)$2.3M
• Sep 2022Grant (prize money)$2.7M

Founders & team

Jason BelletCo-FounderTyler CrouchCo-Founder

Investors

FOUNDER.org, StartX, 10x Group, Artis Ventures, Highland Capital Partners, NTTVC

Tech stack

Adobe Audience ManagerAlpine.JsAmazon Web ServicesApple Icloud MailApple PayCart Functionality

Soley Therapeutics is developing stem cell-secreted factors for the treatment of ischemia-related diseases including myocardial infarction and stroke. These drugs will be administered to patients at the time of heart attack and stroke to minimize the damage in the heart and brain respectively. The company's lead product increases cardiomyocyte (heart muscle) viability, decreases infarct scar size, and improves cardiac function in the acute setting of a heart attack.

Funding rounds

• Jan 2026Series C$200M
• Dec 2020Series B$20M

Founders & team

Yerem YeghiazariansCo-Founder & CEOKurosh AmeriCo-Founder

Investors

Surveyor Capital, HRTG Partners, RWN Management, Breyer Capital, GordonMD Global Investments, Dougleonefamilyfund